Client GrowthOXB now has four clients preparing for commercial launch of CAR-T products, which will yield larger and more predictable vector batch sizes and support mid-term growth ambitions.
Financial PerformanceStrong growth is expected with revenues projected to increase by 42%-44%, aligning with previous guidance.
Market PositioningOXB is seen as a unique and undervalued asset in the UK-listed life science space well positioned to capture a meaningful proportion of the outsourced viral vector supply market in the fast-growing cell and gene therapy space.